Abivax SA - American Depositary Shares (ABVX)

Abivax to be Added to Nasdaq Biotechnology Index

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Abivax Presents Third Quarter 2025 Financial Results

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Abivax Presents First Half 2025 Financial Results

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax Announces Launch of Public Offering

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis  

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax Announces Full Year 2024 Financial Results

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025